

ORIGINAL RESEARCH

TRANSFUSION

Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial

Claudio Pellegrino^{1,2}  | Patrizia Papacci^{1,2} | Carlo Dani³ |
 Francesco Cresi^{4,5} | Giulia Remaschi³  | Giulia Ansaldi⁴ |
 Carmen Giannantonio¹ | Maria Francesca Campagnoli⁴ | Barbara Vania⁴ |
 Marco Fabbri⁶ | Roberta Penta de Vera d' Aragona⁷ | Anna Molisso⁸ |
 Enrico Beccastrini³ | Antonella Dragonetti⁴ | Tina Pasciuto^{1,2} |
 Sabrina Gabbriellini⁶ | Silvia Baroni^{1,2} | Francesca Serrao¹  |
 Velia Purcaro¹ | Genny Raffaeli^{9,10} | Stefania Villa⁹ | Daniele Prati^{9,10}  |
 Isabella Mondello¹¹ | Alessandra Falcone¹¹ | Maria Letizia Patti¹² |
 Tiziana Boggini¹² | Paola Bergamaschi¹² | Iolanda Mozzetta¹ |
 Caterina Giovanna Valentini¹  | Emanuela Locatelli⁴ | Roberto Albiani⁴ |
 Federico Genzano Besso⁴ | Giulia Vanina Cantone¹ | Alessandra Coscia^{4,5} |
 Alfonso Trimarchi¹¹ | Anita Capone¹³ | Stefano Ghirardello¹² |
 Giovanni Vento^{1,2} | Luciana Teofili^{1,2} 

¹Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy

²Università Cattolica del Sacro Cuore, Rome, Italy

³Azienda Ospedaliero Universitaria Careggi, Florence, Italy

⁴Città della Salute e della Scienza, Torino, Italy

⁵Department of Public Health and Pediatrics, Università di Torino, Torino, Italy

⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

⁷Ospedale Santobono Pausilipon, Naples, Italy

⁸Ospedale Evangelico Villa Betania, Naples, Italy

⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

¹⁰Department of Clinical Sciences and Community Health, Università di Milano, Milan, Italy

¹¹Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

¹²Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

¹³Presidio Ospedaliero di Pescara, Pescara, Italy

Abbreviations: A-RBCs, adult donor red blood cells; BPD, bronchopulmonary dysplasia; CB, cord blood; CB-RBCs, cord blood Red blood cells; ELGANs, extremely low gestational age neonates; HbA, adult hemoglobin; HbF, fetal hemoglobin; RBCs, red blood cells; ROP, retinopathy of prematurity.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Transfusion* published by Wiley Periodicals LLC on behalf of AABB.

Correspondence

Luciana Teofili, Università Cattolica del
Sacro Cuore, Rome, Italy.
Email: luciana.teofili@unicatt.it

Funding information

Fresenius Kabi, Grant/Award Number:
5800134-FPG

Abstract

Background: The BORN trial suggested that using cord blood-red blood cells (CB-RBCs) to transfuse severely preterm neonates significantly improves clinical outcomes compared to standard adult donor RBCs (A-RBC).

Study Design and Methods: The study illustrates CB-RBC concentrate production and inventory management across nine CB banks participating in the BORN trial. Quality requirements were those established by the European regulation for leukocyte-depleted RBC concentrates in additive solution. The compliance rate among centers was reported.

Results: During the BORN study, 451 CB-RBC units were processed and 107 were transfused to 69 patients in the intervention arm. However, for 67 transfusion requests, no compatible CB-RBC units were available and adult-RBCs were given. The CB-RBC inventory comprised a minor fraction of CB units collected during the study period, suggesting that many did not meet the protocol-defined volume threshold of 67 mL at collection. Quality control results showed that 84.0% of units achieved target hematocrit (Htc) levels (50–70%), with higher success rates in centers processing more CB units. All centers met quality standards, maintaining residual leukocytes below 1×10^6 and end-storage hemolysis below 0.8% in more than 90% of cases. CB-RBC availability was significantly limited by the time required for bacterial testing results and the need for γ -irradiation.

Discussion: These data suggest that the standardized CB-RBC production is reproducible. Moreover, extending CB-RBC storage to 21 days could maximize the inventory utility.

KEYWORDS

extremely low gestational age neonates, fetal hemoglobin, randomized controlled trial, retinopathy of prematurity, transfusions, umbilical blood

1 | INTRODUCTION

Clinical research in neonatal transfusion has recently challenged the preexisting dogma guiding blood product administration. Particularly in the clinical setting of prematurity, the lack of evidence of the beneficial impact of the liberal use of blood products led to reduced transfusion thresholds for both red blood cell (RBC) and platelet concentrates, while a few indications are nowadays recognized for administering plasma.^{1–4} Likewise, a growing body of evidence established a connection between transfusions and poorer outcomes. Among the underlying pathogenetic mechanisms, the oxidative stress conveyed by blood products themselves seems to be implicated.⁵ One of the consequences of RBC transfusion in extremely low gestational age neonates (ELGANs) is the non-physiological replacement of fetal hemoglobin (HbF) by the adult one (HbA).⁶ Repeated RBC transfusions abnormally increase the HbA levels, and due to the lower oxygen affinity of HbA, it results at the cellular level in a hyperoxic challenge.⁷ This process likely worsens the clinical course of the so-called

“oxidative stress-related diseases,” a group of conditions typically observed in these fragile patients endowed with an impaired antioxidant response.⁸

In a study carried out in 2015, we demonstrated the feasibility of transfusing preterm neonates with RBC concentrates obtained from an allogeneic solidary donated cord blood (CB) unit.⁹ Subsequently, in the proof-of-concept CB-Trip trial, we showed that CB-RBC concentrates raise the Hb concentration without affecting physiological HbF levels.¹⁰ Finally, in the subsequent BORN trial, we have found that transfusing ELGANs with CB-RBCs in their early postnatal life reduces the incidence of more severe forms of retinopathy of prematurity (ROP)¹¹ and bronchopulmonary dysplasia (BPD),¹² the most frequent oxidative stress-related diseases that can adversely affect the long-term quality of life of these patients.¹³

During the abovementioned studies, we refined the methods to process whole CB units into RBC concentrates, to establish the minimum volume of processable units and maximize RBC mass recovery even from low-volume units. Moreover, the BORN trial posed us the challenge of getting

Cord Blood Red Cells, Leukocyte-depleted, in additive solution (CB-RBCs)




FIGURE 1 Main eligibility parameters adopted in the BORN study for processing CB units into RBC concentrates. Processing was performed within 44 h of collection. After leukodepletion and centrifugation, aliquots of RBCs and plasma were used for bacterial and fungal culture tests. RBCs were suspended in SAG-M additive solution and stored at 2–6°C (day 1). CB-RBC units were released after microbial tests were negative (day 5–7), and units were transfused by day 14 to allow γ -irradiation. The units not used for transfusion were used to assess the end-storage hemolysis rate. CB, cord blood; SAG-M, saline, adenine, glucose, mannitol; RBC, red blood cells.

reproducible standards among the different CB banks distributed across the national territory. Considering that only one CB bank operates per region, comparable multicenter operational data are essential to support the clinical translation of this transfusion strategy. This manuscript focuses on the manufacturing feasibility and operational implementation of a CB-RBC inventory for patients in the BORN trial. The information provided can represent a model for future studies on CB-RBC transfusions as well as the basis for implementing this groundbreaking transfusion approach into clinical practice.

2 | MATERIALS AND METHODS

2.1 | Study design

Study design and outcomes have been previously reported.^{13,14} Briefly, BORN was a prospective, randomized, multi-center, double-blinded, controlled trial enrolling preterm neonates delivered at a gestational age (GA) between 24 + 0 and 27 + 6 weeks. Patients were recruited at eight Neonatal Intensive Care Units (NICUs), and CB units were provided by nine CB banks

belonging to the Italian Cord Blood Bank Network. The study was approved by the Ethics Committee of Fondazione Policlinico A. Gemelli IRCCS (ID 4364, Prot. N. 003590/21) and of all participating centers and was registered at <https://clinicaltrials.gov> (NCT05100212). Patients were randomized 1:1 to receive until 29 + 6 weeks postmenstrual age (PMA) either adult donor-RBCs (A-RBCs, control arm) or allogenic CB-RBCs (intervention arm). If compatible CB-RBC units were not available, A-RBC units were administered. After 29 + 6 weeks of PMA, all patients received A-RBCs. Both A-RBC and CB-RBC units were matched for ABO/RhD blood group antigens and γ -irradiated at distribution. Randomization was performed at blood banks through the Research Electronic Data Capture (REDCap) (RRID: SCR_003445) tool hosted at Fondazione Policlinico Universitario A. Gemelli, IRCCS (<https://redcap-irccs.policlinicogemelli.it/>). The arm allocation was not visible to neonatologists. To maintain blinding, A-RBCs and CB-RBCs were distributed in the same type of bags. The primary outcome was the rate of severe ROP (defined as ROP stage 3 or higher in zone I or II and/or the presence of plus disease) at discharge or at 40 weeks of PMA, whichever occurred first.

2.2 | CB-RBC collection and processing

Figure 1 summarizes the flow of CB units from collection to transfusion or discard. Donation eligibility was defined according to the Italian regulation on CB hematopoietic stem cell donation. During pre-donation counseling, couples were informed that CB units deemed unsuitable for transplantation could be processed into RBC concentrates and used to transfuse preterm neonates enrolled in the BORN study. A minority of CB banks adopted a specific consent form, whereas most local Ethics Committees deemed the national informed consent adequate, as it encompassed the research use of cord blood units not suitable for transplantation. CB units were collected in 30 mL of CPD. Criteria for processing into RBC concentrates were (1) total nucleated cell content $<1.2 \times 10^9$ cells and no other criteria that could prevent the transplant use according to Italian regulation (i.e., maternal or paternal history of cancer, autoimmune hereditary or genetic diseases, infectious diseases during pregnancy)¹⁵; (2) volume >67 mL with Hct $>32\%$; (3) no clots or hemolytic plasma; (4) negative direct antiglobulin test; and (5) collection performed within 44 h before processing. The staff responsible for the processing were properly trained before the study. All units were kept stored at 2–6°C until processing, which encompassed (a) the

whole blood filtration through the BioR Flex filters (Fresenius Kabi) and collection of the filtered blood in the CompoFlex 4F RCC Storage System bag; (b) the centrifugation of filtered blood at 2979g, for 10 min, at room temperature; (c) the fractionation with the Compomat G5 cell separator (Fresenius Kabi) with two different pre-specified programs depending on whether the post-filtration volume was $<$ or >80 mL; (d) the RBCs recovery and suspension in saline, adenine, glucose, mannitol (SAG-M) additive solution in a 2:1 ratio. The quality standards for CB-RBCs were the same established by the European regulation for leukocyte-depleted RBC concentrates in additive solution and included residual leukocyte content after filtration $<10^6$ cells (as evaluated by flow cytometry according to center standard procedures), Hct 50–70%, and end-storage hemolysis rate $<0.8\%$ of the initial Hb content in a minimum of 90% of units tested.¹⁶ After processing, all CB-RBC concentrates were tested for bacterial and fungal contamination, using pediatric BacT/Alert blood culture bottles and automated detection system (Biomérieux, Marcy-l'Etoile, Lyon, France), and stored at 2–6°C temperature. Criteria for release were: negative serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis, and negative nucleic acid test for HIV, HBV, and HCV on maternal plasma samples collected at the time of delivery, and negative microbiological test. The maximum storage length was 14 days to allow γ -irradiation.¹⁶ Non-transfused units were used to assess the end-storage hemolysis level (Figure 1).

2.3 | Data collection

Data were collected in REDCap in a dedicated eCRF. Parameters at collection (date and time, volume, complete cell blood count [CBC], ABO/Rh typing), at processing (date and time, RBC concentrate volume, CBC, residual leukocytes, free hemoglobin), and at the end of the storage (CBC, free hemoglobin) were recorded.

2.4 | Statistical analysis

Continuous variables were expressed as median and relative 25th–75th percentile range (interquartile range [IQR]), and categorical variables as proportions (n , %). For differences between groups Fisher's exact test for categorical variables and the Mann–Whitney U test for continuous variables were used. Correlation was expressed by the Spearman's or Pearson's correlation coefficient, as appropriate (r). Two-sided tests were applied, and the statistical




FIGURE 2 Total number of cord blood units collected at participating banks, number of units processed into CB-RBC concentrates for the BORN trial, and number of enrolled patients in the corresponding NICUs, when present. Data are given on a base-2 logarithmic scale. CB-RBCs, cord blood-red blood cells; NICUs, Neonatal Intensive Care Units.

level of significance was set at 0.05. Quality control measurements were performed on subsets of units. All available quality control data were included without imputation of missing data and results were reported based on the number of units tested. NCSS10 Statistical Software 2015 (NCSS, LLC., Kaysville, Utah, USA, [ncss.com/software/ncss](https://www.ncss.com/software/ncss)) and GraphPad Prism version 10.0.0 (GraphPad Software, Boston, Massachusetts, USA, www.graphpad.com) were used.

3 | RESULTS

3.1 | CB-RBC inventory and the impact on study management

The BORN study started in December 2021 and ended in December 2024. During the 3-year study period, 451 CB-RBC units were produced by nine CB banks. A total of 18 units (3.9%) were found positive at microbial testing and were therefore not released: the positivity rate among centers ranged from 0% to 10.3% ($p < 0.001$ at χ^2 test). The number of units processed was only a minor fraction of that of 5467 units collected at the same sites during the study period (data of the Italian Cord Blood Network available at <https://www.centronazionalesangue.it/rapporti-di-attivita-delle-banche-sco/>) (Figure 2): the average proportion of collected CB units processed into CB-RBCs was 8.4% (IQR 6.0–10.6), with a high variability among centers, ranging from 2.7% to 18.9% ($p < 0.001$ at χ^2 test). This finding could be explained only in part by the decision to prioritize O-group units for fractionation (70.5%, Table 1). The number of processed units was proportional to the amount of CB units collected at CB bank

($r = 0.742$, Figure 3A) and of patients enrolled at the corresponding NICU ($r = 0.757$, Figure 3B).

During the study, a total of 458 RBC units were transfused to 118 out of 142 enrolled patients: 240 to 60 neonates in the control arm and 218 to 58 patients in the intervention arm. Notably, 431 (94.1%) transfusions were administered before 32 weeks of age, and 402 (87.8%) before 30 weeks. In total, 351 transfusions were A-RBCs and 107 CB-RBCs. CB units were released at a median age of 7 days (IQR 5–11) and were irradiated at distribution. Regarding transfusions given before 30 weeks of age, which marked the end of the intervention period, patients in the experimental arm received 80 CB-RBCs and 67 A-RBC units. These latter were administered because no CB-RBC units were available at the time of the transfusion request, despite the large number of units processed. As reported, the BORN study outcomes were significantly impacted by these protocol deviations.¹³ In fact, 24 (42.8%) out of 56 evaluable patients in the intervention arm received also A-RBCs, explaining the similar incidence of severe retinopathy at intention-to-treat analysis.¹³

3.2 | Main characteristics of CB units and quality parameters of CB-RBC concentrates

Table 1 illustrates the characteristics of the 451 CB units at collection and their ABO/Rh typing distribution. Median volume at collection was 90 mL (IQR 76–102), Hct 36.2 (IQR 34.3–38.5), and Hb concentration 11.4 g/dL (IQR 10.8–12.2). A total of 437 (96.9%) units met protocol-defined volume and Hct criteria (volume >67 mL and hematocrit [Hct] >32%), and 14 (3.1%) did not, with a different distribution among centers ($p < 0.001$ at χ^2 test).

Leukodepletion was performed by filtering whole CB units before fractionation. The BioR Flex filter, marketed for RBC concentrates, was used for this purpose due to its smaller size compared to whole-blood filters. Moreover, preliminary data showed that it resulted in a better RBC mass recovery than filtering RBC concentrates, as we had performed in previous studies.^{11,12} Prior to study initiation, the off-label use of the BioR Flex filter was validated at the coordinating center and the results are summarized in Table 2. A total of 40 CB units with a median volume of 78 mL (IQR 69–94) and a median Hct of 37.3% (IQR 34.7–39.2) were filtered in an average time of 3.8 min (IQR 3.6–4.3). Filtration resulted in a median volume loss of 27% (IQR 23–32), with a median post-filtration volume of 58 mL (IQR 48–73) (Table 2). The recovery of the RBC mass was 72.3% (IQR 67.0–77.1).

TABLE 1 Parameters of the 451 cord blood units collected and processed in the 9 blood banks participating in the BORN study.

	A	B	C	D	E	F	G	I	H	TOT
	N 30	N 47	N 30	N 20	N 98	N 14	N 25	N 84	N 103	N 451
Volume, mL	89.0 (81.7–99.3)	103.0 (95.0–118.0)	88.5 (69.5–115.5)	94.0 (83.8–102.8)	83.5 (73.0–99.2)	69.0 (58.7–88.0)	88.0 (76.3–102.8)	95.0 (79.0–107.0)	86.0 (76.0–96.0)	90.0 (76–102)
Hct, %	36.2 (34.3–37.8)	34.6 (32.9–36.3)	35.7 (33.9–37.1)	37.1 (34.7–38.7)	36.0 (34.0–38.1)	36.3 (33.9–39.4)	35.4 (33.2–37.6)	36.4 (34.7–38.5)	37.3 (35.8–40.7)	36.2 (34.3–38.5)
RBC mass, mL	32.0 (28.7–37.2)	37.0 (32.0–42.0)	32.5 (24.5–41.5)	33.0 (30.2–39.2)	31.0 (25.8–36.2)	25.0 (19.8–31.0)	32.0 (27.3–37.0)	34.0 (28.0–39.0)	33.0 (27.3–37.0)	33.0 (27.0–38.0)
Hb, g/dL	11.3 (10.9–12.0)	11.4 (10.6–12.0)	11.3 (10.8–11.7)	11.9 (11.0–12.6)	11.0 (10.0–11.6)	11.7 (10.3–12.6)	11.1 (10.3–13.2)	11.7 (11.1–12.7)	11.5 (10.9–12.5)	11.4 (10.8–12.2)
Leukocytes, 10 ⁹ /L	11.1 (10.1–13.0)	9.3 (7.7–10.9)	10.1 (9.6–12.8)	9.4 (7.2–11.6)	10.0 (8.2–11.4)	10.8 (9.3–12.5)	10.1 (8.9–11.9)	10.8 (8.4–12.8)	10.3 (9.0–12.2)	10.3 (8.7–12.0)
Platelets, 10 ⁹ /L	220 (191–260)	202 (178–224)	221 (201–255)	195 (160–243)	201 (167–227)	216 (155–246)	203 (159–226)	240 (204–282)	225 (195–277)	214 (183–250)
Compliant for starting volume ^a	30 (100)	47 (100)	24 (80)	20 (100)	98 (100)	11 (78.6)	25 (100)	84 (100)	98 (95.1)	439 (96.)
Positive at microbial testing	0 (0)	1 (2.3)	3 (10.3)	0 (0)	8 (8.3)	1 (7.1)	0 (0)	0 (0)	5 (4.9)	18 (3.9)
Typed units	N 30	N 47	N 30	N 20	N 98	N 10	N 25	N 75	N 103	N 438
O positive	20 (66.7)	35 (74.5)	16 (53.3)	7 (35.0)	65 (67.7)	4 (40.0)	9 (36.0)	49 (65.3)	67 (65.0)	273 (62.3)
O negative	3 (10)	6 (12.8)	4 (13.3)	1 (5.0)	6 (6.3)	0 (0)	1 (4.0)	9 (12.0)	6 (5.8)	36 (8.2)
A positive	7 (23.3)	5 (10.6)	7 (23.3)	7 (35.0)	17 (17.3)	4 (40.0)	7 (28.0)	8 (10.7)	24 (23.3)	86 (19.6)
A negative	0 (0)	0 (0)	1 (3.3)	1 (5.0)	5 (5.1)	1 (4.0)	4 (16.0)	3 (4.0)	3 (2.9)	18 (4.1)
B positive	0 (0)	0 (0)	2 (6.6)	2 (10.0)	4 (4.1)	0 (0)	3 (12.0)	5 (6.7)	3 (2.9)	19 (4.3)
B negative	0 (0)	1 (2.1)	0 (0)	2 (10.0)	0 (0)	1 (10.0)	1 (4.0)	1 (1.3)	0 (0)	6 (1.3)

Abbreviations: Hb, hemoglobin; Htc, hematocrit; RBC, red blood cells; WBC, white blood cells.

^aTo be eligible for fractionation, cord blood units should have a starting volume >67 mL with a hematocrit >32%. Data are expressed as median (25th to 75th percentile range) or *n* (%).




FIGURE 3 Number of cord blood units processed at different centers. (A) Correlation with the number of units collected at cord blood banks. (B) Correlation with the number of patients enrolled at the corresponding neonatal intensive care unit.

Leukodepletion was evaluated by flow cytometry count of residual white blood cells (WBCs) in 31 CB units. Results showed a 99.9% reduction (IQR 99.9–99.9) of the WBC content, and a median residual per unit of 0.014×10^6 WBCs (IQR 0.005–0.036). In total, 30 out of 31 evaluated units (96.8%) in the validation protocol had a WBC residual $<1 \times 10^6$ (Table 2). Filtration also resulted in a substantial reduction in platelet content, removing 88.8% (IQR 84.1–90.7) of the initial platelets.

Table 3 illustrates the main parameters of RBC concentrates fractionated during the BORN study. All units were processed within 44 h from collection, with a median interval of 26.0 h (IQR 20.4–35.8). RBC concentrates had a median volume of 39 mL (IQR 30–50), a median Hct of 56.1 (IQR 52.3–59.4), and a median Hb content per unit of 6.8 g (IQR 5.2–8.5). The RBC mass recovery in RBC concentrates was 64.6% (IQR 58.4–72.0) of the initial RBC mass and was slightly related to the volume ($r = 0.099$, $p = 0.039$) and RBC mass ($r = 0.111$,

TABLE 2 Pre-study validation of leukodepletion.

	CB units N 40
Pre-filtration volume, mL	77.1 (70.4–94.3)
Pre-filtration Hct, %	37.3 (34–7–39.2)
Pre-filtration RBC mass, mL	29.0 (24.8–34.3)
Pre-filtration WBCs, 10^6 /unit	754 (606–998)
Pre-filtration PLT, 10^9 /unit	17.4 (14.4–20.7)
Post-filtration volume, mL	55.7 (47.6–72.9)
Volume loss, %	27.3 (22.9–32.0)
Post-filtration Hct, %	36.0 (34.2–38.9)
Post-filtration RBC mass, mL	21.0 (16.7–27.2)
RBC mass recovery, %	72.3 (67.0–77.1)
Post-filtration WBCs, 10^6 /unit ^a	0.014 (0.005–0.036)
WBC removal, % ^a	99.9 (99.9–99.9)
Compliant for residual WBC ^a	30 (96.8)
Post-filtration PLT, 10^9 /unit	1.8 (1.4–2.9)
PLT removal, %	88.8 (84.1–90.7)

Abbreviations: CB, cord blood; Hct, hematocrit; RBC, red blood cells; WBC, white blood cells.

^aData relative to 31 CB units. Data are expressed as median (25th to 75th percentile range) or n (%).

$p = 0.021$) at collection. As expected, the volume of CB-RBC concentrates was proportional to the volume at collection ($r = 0.705$, $p = 0.001$), to the initial Hct value ($r = 0.348$, $p = 0.001$), and RBC mass ($r = 0.747$, $p < 0.001$). Similarly, the final Hb content of CB-RBC concentrates was proportional to the volume of the unit at collection ($r = 0.705$, $p < 0.001$), to the Hct value ($r = 0.348$, $p < 0.001$), RBC mass ($r = 0.783$, $p < 0.001$), and Hb content ($r = 0.793$, $p < 0.001$).

The platelet content in CB-RBC concentrates was 1.9×10^9 /unit (IQR 0.9–3.7), confirming that near 90% of the initial platelet content was removed after filtration. The interval between collection and processing seemed to influence the platelet reduction rate, with a larger decrease after longer storage ($r = 0.153$, $p = 0.001$).

Regarding the RBC concentrate quality requirements, 379 of 451 (84.0%) CB-RBC units had post-processing Hct values between 50% and 70%, with significantly different compliance rates among centers ($p < 0.001$ at χ^2 test). Centers with higher volume activity produced CB-RBC units with significantly higher Hct values ($r^2 = 0.05$ at linear regression analysis between units processed and Hct values of produced CB-RBCs, $p < 0.001$), suggesting that center performances could be enhanced by expanding practice. CB units that did not meet protocol-defined criteria at collection (volume >67 mL and Hct $>32\%$) more frequently produced CB-RBC concentrates with

TABLE 3 Processing data and quality controls of CB-RBC units produced during the BORN study.

	A (n 30)	B (n 47)	C (n 30)	D (n 20)	E (n 98)	F (n 14)	G (n 25)	I (n 84)	H (n 103)	TOT 451
Interval form collection, hours	30.5 (20.7–38.8)	28.3 (26.0–30.4)	25.8 (24.0–32.6)	22.6 (17.0–37.9)	31.8 (21.1–37.9)	21.8 (1.0–40.6)	23.0 (19.2–29.5)	24.6 (18.4–32.0)	24.1 (18.8–36.0)	26.0 (20.4–35.8)
CB-RBC volume, mL	39.5 (30.7–48.5)	44.0 (34.0–50.0)	53.0 (44.5–61.0)	35.0 (29.0–40.2)	32.5 (28.0–44.0)	32 (29.3–39.0)	46.5 (30.2–57.0)	42.0 (30.2–50.0)	38.0 (30.5–45.5)	39.0 (30.0–50.0)
Hct, %	57.6 (54.2–60.7)	58.0 (56.0–59.5)	47.5 (44.3–52.7)	57.0 (52.4–58.5)	56.0 (52.0–59.0)	53.9 (37.9–61.8)	49.0 (41.4–52.6)	55.0 (52.6–56.6)	58.3 (55.4–61.9)	56.1 (52.3–59.4)
RBC mass, mL	22.0 (18.0–27.5)	25.0 (20.0–29.0)	27.0 (20.0–32.0)	20.5 (15.3–22.0)	18.0 (14.0–24.0)	16.0 (10.5–22.0)	18.5 (13.5–26.25)	22.0 (16.2–28.0)	22.0 (17.0–27.0)	21.6 (17.0–27.0)
RBC mass recovery, %	68.6 (63.4–75.7)	65.8 (62.2–69.6)	84.4 (69.3–96.2)	57.5 (50.0–64.5)	59.4 (53.7–69.4)	64.0 (53.0–71)	62.4 (48.0–83.3)	62.8 (58.4–69.9)	67.7 (60.8–73.1)	64.6 (58.4–72.0)
Hb/unit, g	6.9 (5.5–8.6)	8.2 (6.4–9.4)	8.3 (6.2–10.3)	6.4 (5.3–7.2)	5.6 (4.3–7.6)	5.5 (4.7–6.9)	6.0 (4.0–8.9)	7.3 (5.3–9.1)	6.9 (5.2–8.5)	6.8 (5.2–8.5)
Platelets, 10 ⁹ /unit	2.3 (1.3–3.3)	3.9 (2.7–5.1)	2.3 (0.8–4.1)	1.6 (0.9–2.5)	1.7 (0.9–3.0)	2.6 (1.0–53.7)	1.2 (0.9–2.6)	2.4 (1.5–4.4)	1.0 (0.5–1.9)	1.9 (0.9–3.2)
Platelet removal, %	87.4 (83.9–91.5)	82.5 (77.9–85.5)	87.8 (82.9–94.7)	90.4 (86.6–94.5)	89.7 (84.3–93.1)	87.0 (81.8–91.4)	90.9 (86.1–95.0)	88.2 (84.7–92.6)	94.1 (91.5–96.6)	89.6 (84.8–93.6)
Compliant for Htc values ^a	29 (96.7)	47 (100)	10 (33.3)	18 (90.0)	85 (86.7)	9 (64.2)	9 (36.0)	78 (92.8)	94 (91.2)	379 (84.0)
Compliant for residual WBC	30/30 (100)	45/46 (97.8)	29/29 (100)	20/20 (100)	95/95 (100)	9/9 (100)	24/24 (100)	76/76 (100)	9/9 (100)	337/338 (99.7%)
End-stage hemolysis	0.23 (0.01–0.47)	0.24 (0.17–0.35)	0.39 (0.31–0.63)	0.51 (0.41–0.65)	0.33 (0.28–0.62)	NR	NR	0.45 (0.40–0.51)	0.29 (0.22–0.41)	0.39 (0.25–0.51)
Compliant/tested for end storage hemolysis ^a	10/10 (100)	7/8 (87.5)	20/22 (90.9)	16/17 (94.1)	17/17 (100)	NA	NA	18/19 (94.7)	30/30 (100)	117/123 (94.3)

Note: Only CB units collected <44 h were eligible for fractionation. Data are expressed as median (25th to 75th percentile range) or *n* (%).
Abbreviations: CB-RBCs, cord blood-red blood cells; Hb, hemoglobin; Htc, hematocrit; NA, not assessed; NR, not reported; WBC, white blood cell.
^aQuality requirements for CB-RBCs included Htc between 50% and 70%, residual WBC <10⁶ per unit, and hemolysis rate after 14 days of storage below 0.8% of the initial Hb in 90% of the units evaluated.

low Htc (64.3% of CB-RBCs with Htc <50% vs. 12.6% among compliant units, $p < 0.001$). In all centers, more than 90% of tested CB-RBC units had residual WBCs $<1 \times 10^6$ with no difference among them ($p = 0.606$ at χ^2 test). Similarly, the end-storage hemolysis rate was below 0.8% of the initial hemoglobin content in 117 of 123 (94.3%) investigated units, without differences among centers ($p = 0.251$ at χ^2 test). The end-storage hemolysis rate was not related to unit characteristics, including CB volume, interval between collection and processing, CB-RBC unit volume, Hb content, and residual platelets and WBCs.

4 | DISCUSSION

The rationale of the BORN trial revolutionizes the approach to the transfusion therapy of extremely preterm neonates.¹³ The core concept is to ensure that physiologically elevated HbF levels persist in these patients, even after RBC transfusions. The outcome assessment in patients allocated to the experimental arm of the BORN study was severely affected by a high rate of protocol deviations, with more than 40% also receiving standard RBC transfusions.¹³ As a result, the advantage of CB-RBC transfusions did not emerge across the entire patient population (intention-to-treat analysis) but only in the subgroup of patients who were properly transfused according to the arm allocation (per-protocol analysis).¹³ Despite these limitations, the potential clinical benefit of this novel transfusion approach for severe ROP and BPD has attracted significant attention.^{17–21} Sharing data on the 451 CB units collected and processed during the BORN study period, along with highlighting the challenges encountered, could help inform the design of future clinical trials exploring this transfusion approach.

As stated above, an important issue encountered in the BORN study was the insufficient availability of CB-RBC units for patients in the intervention arm, which was unexpected given that 5467 CB units were collected in the same period at participating CB banks. Among the 451 CB-RBC units fractionated during the study, only 107 were transfused, whilst for 67 transfusion requests for patients in the intervention arm there were no available CB-RBC units. The large number of collected units that were not processed into RBCs suggests that many of them did not meet the protocol-defined criteria. The BORN study inventory included only units collected in the previous 44 h: this interval was set according to the threshold of 48 h generally accepted for transplant units, and estimating a total processing duration of 4 h. Nevertheless, it cannot be excluded that also CB collected earlier could be suitable for transfusion and extending this

window could improve availability without compromising product quality.²² An additional eligibility criterion for the processing was the volume. It is acknowledged that the timing of cord clamping significantly influences CB volume and cell content in both vaginal and cesarean section delivery, with either in utero or ex utero placenta collection.^{23–27} For vigorous, healthy neonates, WHO, ACOG, and NICE strongly recommend delaying cord clamping for at least 1 min, especially in low-resource settings with limited access to iron-rich foods.^{28–30} This approach was followed at all centers participating in the BORN study, and the median reported CB unit volume of 90 mL (IQR 76–102) confirms that delaying cord clamping as recommended is still compatible with the collection of a CB unit suitable for processing into RBC concentrates. However, it is conceivable that the availability of CB units suitable for transfusion may be substantially increased by improving collection methods. Interestingly, a recent study on CB solidarity donation illustrated novel approaches combining empathetic, story-based care with efficient, waste-reducing workflows, which can effectively improve trust, patient engagement, and staff satisfaction, leading to significantly higher donation rates and quality units.³¹ The fractionation method used in the BORN study produces a 25–30% loss of the initial CB unit volume during filtration. Considering a transfusion dose of 20 mL/kg,³² it was estimated that fractionating CB units with a minimum volume of 67 mL and an Htc value of 32% would yield CB-RBC concentrates suitable for clinical use. As expected, CB-RBC volume and total Hb content depended on the volume and RBC mass content of the starting units. Nevertheless, centers processing more units produced RBC concentrates with higher Htc, denoting that expanding practice may improve processing performances.

An additional issue significantly affecting the CB-RBC inventory during the BORN study was the units' short shelf life. Overall, in vitro storage studies indicate that the shelf-life of CB-RBCs may be limited to 21 days.^{33–35} CB-RBC units could not be released until negative bacterial test results were available, requiring 5–7 days. In addition, all RBC units transfused during the BORN study were irradiated at distribution; since units older than 14 days cannot be irradiated, this further limited the distribution time window to 7–9 total days. Pre-storage leucocyte depletion of blood components is recommended to reduce adverse transfusion reactions, limit transfusion-transmitted infections, and improve RBC storage.³⁶ Whole CB filtration resulted in highly satisfactory leukodepletion, with more than 99% of units having less than 1×10^6 residual WBCs, the limit still recommended by the most recent EDQM guidelines for

leukocyte-depleted additive solution RBC concentrates.³⁷ Moreover, residual WBC were below 10^5 cells/unit in more than 90% of cases. It is generally acknowledged that blood components can be considered CMV-safe if they contain $<5 \times 10^6$ leucocytes/unit.³⁸ Accordingly, a total WBC count $<1 \times 10^6$ /unit is considered CMV-safe and suitable for neonatal transfusion.³⁹ Nevertheless, unless CMV infection occurs during pregnancy, CB-RBCs convey no risk for CMV transmission by the donor. In contrast to blood components from adult individuals, residual WBCs in CB-RBCs exhibit a naïve and tolerant phenotype, typical of neonatal cells.⁴⁰ All these considerations question the need to irradiate CB-RBC units to prevent transfusion-associated graft-versus-host disease (TA-GvHD).⁴¹ Neonates in general, and preterm neonates in particular, are considered at risk for TA-GvHD due to anecdotal cases of TA-GvHD described following intrauterine transfusion and neonatal exchange blood transfusion.⁴² Accordingly, Italian guidelines recommend γ -irradiated blood components for these patients.³² An analysis of the last 10 years' reports from the UK national hemovigilance scheme, Serious Hazards of Transfusion (2010–2019), evidenced no TA-GvHD among 956 incidents of failure to receive irradiated components, suggesting a protective role for modern processing methods.⁴³ Considering these aspects, more recent guidelines on TA-GvHD prevention omit irradiation for neonates without a known or suspected defect of cellular immunity.⁴⁴ An additional aspect to avoid irradiation of CB units is that scarce data are available on the damage to irradiated CB-RBCs,³³ whereas it is well known that irradiation impairs the quality of adult RBCs, increasing hemolysis and impairing oxygen delivery.^{45,46}

CB-RBC concentrates are a novel blood product and no specific quality standards are available in the current blood product quality guidelines.³⁷ Apart from the Hct values, all nine centers in the BORN study met compliance for residual WBCs. Seven of them also complied with end-storage hemolysis rates, whereas two centers did not report the data. Overall, these findings suggest that the processing method used in the BORN study might be suitable for scaling CB transfusion for a broader clinical use. The new European regulation for substances of human origin favors the introduction of innovative blood components adopting the GAPP (facilitating the Authorization of Preparation Process) methodology by European National competent authorities. GAPP includes a standardized assessment across member states to evaluate the safety and efficacy of new products, and harmonized procedures to determine the level of clinical evidence (from *in vitro* validation to clinical follow-up) required to authorize the new preparation process.⁴⁷ Indeed, to promote CB-RBC transfusion for preterm

neonates from a restricted experimental setting to wider clinical use, it will be necessary to obtain competent authority authorization through the GAPP methodology. The GAPP methodology uses the EuroGTP II Interactive Assessment Tool to determine the novelty and risks associated with new components or preparations, as well as the eventual measures to assure their safety and efficacy.⁴⁸ According to available processing and clinical data, the EuroGTP II tool estimated that the use of this novel component has a low risk, which can be further minimized by careful monitoring of processing data and transfusion effects.⁴⁷

Finally, it should be mentioned that during the BORN study we used eligibility criteria set by the Italian regulatory framework for donating CB hematopoietic stem cells.¹⁵ The assessment includes the evaluation of paternal and maternal clinical history and is focused on a wide range of hereditary and genetic diseases potentially transmitted by the graft. Eligibility criteria for donating CB for transfusion could be appropriately revised, limiting the assessment to maternal history and focusing on transfusion-transmissible diseases. Hopefully, this simplification could lead to a greater propensity among pregnant women to donate CB.

In conclusion, CB-RBC transfusion for ELGANs is supported by a robust biological rationale. Preliminary clinical data suggest that HbF exerts a physiological protective effect in these patients, while evidence regarding product quality and safety remains highly encouraging.¹³ In the future, operational refinements such as more rapid methods to detect microbial contamination or CB-RBC-specific pathogen inactivation technologies will undoubtedly improve the utilization of the CB inventory. Presently, the scalability of the CB processing, as designed in the BORN study, paves the way to next steps for an initial implementation of this transfusion approach under the precautionary monitoring of the National competent authority. Data from the present study suggest that hospitals with large patient populations and high CB collection capacity are likely better suited for the initial phase of the implementation. Moreover, increasing awareness among donors and midwives through targeted educational initiatives is essential to enhance the supply of CB units. Additionally, collaborating with neonatologists and preterm neonate parents' associations could prove instrumental in promoting the informed altruistic CB donation.

ACKNOWLEDGMENTS

BORN investigators are indebted to the personnel of NICUs and Cord Blood Banks participating in BORN, whose valuable work makes the study possible. Moreover, they express deep empathy and gratitude to parents

of all “born too soon” babies enrolled in BORN. Open access publishing facilitated by Università Cattolica del Sacro Cuore, as part of the Wiley - CRUI-CARE agreement.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Claudio Pellegrino  <https://orcid.org/0000-0002-1614-5576>

Giulia Remaschi  <https://orcid.org/0000-0001-6235-4486>

Francesca Serrao  <https://orcid.org/0000-0002-7115-1469>

Daniele Prati  <https://orcid.org/0000-0002-2281-7498>

Caterina Giovanna Valentini  <https://orcid.org/0000-0002-7022-5366>

Luciana Teofili  <https://orcid.org/0000-0002-7214-1561>

REFERENCES

- Carson JL, Stanworth SJ, Dennis JA, Fergusson DA, Pagano MB, Roubinian NH, et al. Transfusion thresholds and other strategies for guiding red blood cell transfusion. *Cochrane Database Syst Rev*. 2025;10(10):CD002042. <https://doi.org/10.1002/14651858.CD002042.pub6>
- van der Staaij H, Prosepe I, Caram-Deelder C, Keogh RH, Deschmann E, Dame C, et al. Individualized prediction of platelet transfusion outcomes in preterm infants with severe thrombocytopenia. *JAMA*. 2025;334(14):1267–77. <https://doi.org/10.1001/jama.2025.14194>
- Houben NAM, Fustolo-Gunnink S, Fijnvandraat K, Caram-Deelder C, Aguar Carrascosa M, Beuchée A, et al. Plasma transfusions in neonatal intensive care units: a prospective observational study. *Arch Dis Child Fetal Neonatal Ed*. 2025;110(5):452–9. <https://doi.org/10.1136/archdischild-2024-327926>
- Houben NAM, Caram-Deelder C, Lopriore E, Fustolo-Gunnink S. INSPIRE contributors. The whole is greater than the sum of its parts: rethinking our approach to neonatal transfusion research. *Transfusion*. 2025; 65(11):2021–3. <https://doi.org/10.1111/trf.18432>
- Jiang Q, Wen J, Ding Y, Cui H. From vulnerability to resilience: unraveling the role of oxidative stress in preterm brain injury. *Ital J Pediatr*. 2025;51(1):232. <https://doi.org/10.1186/s13052-025-02079-4>
- De Halleux V, Truttmann A, Gagnon C, Bard H. The effect of blood transfusion on the hemoglobin oxygen dissociation curve of very early preterm infants during the first week of life. *Semin Perinatol*. 2002;26(6):411–5. <https://doi.org/10.1053/sper.2002.37313>
- Pellegrino C, Papacci P, Beccia F, Serrao F, Cantone GV, Cannetti G, et al. Differences in cerebral tissue oxygenation in preterm neonates receiving adult or cord blood red blood cell transfusions. *JAMA Netw Open*. 2023;6(11):e2341643. <https://doi.org/10.1001/jamanetworkopen.2023.41643>
- de Almeida VO, Pereira RA, Amantéa SL, Rhoden CR, Colvero MO. Neonatal diseases and oxidative stress in premature infants: an integrative review. *J Pediatr*. 2022;98(5):455–62. <https://doi.org/10.1016/j.jpeds.2021.11.008>
- Bianchi M, Giannantonio C, Spartano S, Fioretti M, Landini A, Molisso A, et al. Allogeneic umbilical cord blood red cell concentrates: an innovative blood product for transfusion therapy of preterm infants. *Neonatology*. 2015;107(2):81–6. <https://doi.org/10.1159/000368296>
- Teofili L, Papacci P, Orlando N, Bianchi M, Molisso A, Purcaro V, et al. Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TrIP study. *Br J Haematol*. 2020;191(2):263–8. <https://doi.org/10.1111/bjh.16851>
- Glaser K, Härtel C, Dammann O, Herting E, Andres O, Speer CP, et al. Erythrocyte transfusions are associated with retinopathy of prematurity in extremely low gestational age newborns. *Acta Paediatr*. 2023;112(12):2507–15. <https://doi.org/10.1111/apa.16965>
- Zhang Z, Lu S, Fang X, Zhang H. Red blood cell transfusion frequency and the risk and severity of bronchopulmonary dysplasia in preterm infants: a retrospective cohort study. *BMC Pediatr*. 2025;25(1):679. <https://doi.org/10.1186/s12887-025-05797-0>
- Teofili L, Papacci P, Pellegrino C, Dani C, Cresi F, Remaschi G, et al. Cord red blood cell transfusions for severe retinopathy in preterm neonates in Italy: a multicenter randomized controlled trial. *EClinicalMedicine*. 2025;87:103426. <https://doi.org/10.1016/j.eclinm.2025.103426>
- Teofili L, Papacci P, Orlando N, Bianchi M, Pasciuto T, Mozzetta I, et al. BORN study: a multicenter randomized trial investigating cord blood red blood cell transfusions to reduce the severity of retinopathy of prematurity in extremely low gestational age neonates. *Trials*. 2022;23(1):1010. <https://doi.org/10.1186/s13063-022-06949-8>
- Ministero della Salute. Disposizioni relative ai requisiti di qualità e sicurezza del sangue e degli emocomponenti. Rome: Gazzetta Ufficiale della Repubblica Italiana N 300, 28 Dec 2015 [Cited 2026 Mar 5]. Available from: www.gazzettaufficiale.it
- European Directorate for the Quality of Medicines & Health-Care (EDQM). Guide to the preparation, use and quality assurance of blood components. 20th ed. Strasbourg: Council of Europe; 2020.
- Lopriore E, Huisman E, Zwaginga JJ, Snijder PM, Reiss IK, Stanworth S. Allogeneic cord blood transfusions for extremely preterm neonates: an extremely promising proof of concept. *Br J Haematol*. 2020;191(2):150–1. <https://doi.org/10.1111/bjh.16918>
- González EG, Casanova MA, Samarkanova D, Aldecoa-Bilbao V, Teresa-Palacio M, Busquets EF, et al. Feasibility of umbilical cord blood as a source of red blood cell transfusion in preterm infants. *Blood Transfus*. 2021;19(6):510–7. <https://doi.org/10.2450/2020.0169-20>
- Bahr TM, Ohls RK, Christensen TR, Monson MC, Page JM, Dabbling HA, et al. Three studies needed to inform the design of the U-BET (umbilical cord blood for extremely

- low-gestational-age transfusions) clinical trial. *J Perinatol*. 2026;46(1):55–60. <https://doi.org/10.1038/s41372-025-02345-7>
20. Zeiler B, Bahr TM, Esplin SD, Hartnett ME, Ilstrup SJ, Ohls RK, et al. The nucleated red blood cell count at birth, the volume of red cell transfusions received, and the risk of developing retinopathy of prematurity. *J Perinatol*. 2025;45(12):1809–15. <https://doi.org/10.1038/s41372-025-02519-3>
 21. Benoune M. EBNEO commentary: cord blood red cell transfusions and severe retinopathy of prematurity in preterm neonates. *Acta Paediatr*. 2026;111(3):748–9. <https://doi.org/10.1111/apa.70376>
 22. Zhurova M, Akabutu J, Acker J. Quality of red blood cells isolated from umbilical cord blood stored at room temperature. *J Blood Transfus*. 2012;2012:102809. <https://doi.org/10.1155/2012/102809>
 23. Manchanayake GS, Busquets EF, Buendia AG, Ferrer P, Palomar G, Pelegay MJ, et al. Efficiency assessment of cord blood banking and compatibility with delayed cord clamping. *Blood Transfus*. 2025;23:242–9.
 24. Ciubotariu R, Scaradavou A, Ciubotariu I, Tarnawski M, Lloyd S, Albano M, et al. Impact of delayed umbilical cord clamping on public cord blood donations: can we help future patients and benefit infant donors? *Transfusion*. 2018;58:1427–33.
 25. Allan DS, Scrivens N, Lawless T, Mostert K, Oppenheimer L, Walker M, et al. Delayed clamping of the umbilical cord after delivery and implications for public cord blood banking. *Transfusion*. 2016;56:662–5.
 26. Frändberg S, Waldner B, Konar J, Rydberg L, Fasth A, Holgersson J. High quality cord blood banking is feasible with delayed clamping practices. The eight- year experience and current status of the national Swedish Cord Blood Bank. *Cell Tissue Bank*. 2016;17:439–48.
 27. Verbeek L, Cortesi V, Daelen JV, Klei T, Houben NAM, Huisman EJ, et al. Volume of umbilical cord blood collection in the era of delayed cord clamping: a multicentre, prospective, feasibility study. *Arch Dis Child Fetal Neonatal ed*. 2025;111(1):F82–6. <https://doi.org/10.1136/archdischild-2025-328598>
 28. World Health Organization. Guideline: delayed umbilical cord clamping for improved maternal and infant health and nutrition outcomes. Geneva: World Health Organization; 2014.
 29. American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Delayed umbilical cord clamping after birth: ACOG Committee opinion, number 814. *Obstet Gynecol*. 2020;136(6):e100–6. <https://doi.org/10.1097/AOG.0000000000004167>
 30. National Institute of Care Excellence Guidelines. [Cited 2026 Mar 7]. Available from: <https://www.nice.org.uk/guidance/qs105/chapter/Quality-statement-6-Delayed-cord-clamping>
 31. Dealberti D, Bosoni D, Ghirotto V, Pisani C, Sanjinez JOSP, Fadda B, et al. The role of narrative medicine and lean management in umbilical cord blood donation: a story of success. *Healthcare*. 2025;13(20):2567.
 32. Girelli G, Antoncicchi S, Casadei AM, Del Vecchio A, Isernia P, Motta M, et al. Recommendations for transfusion therapy in neonatology. *Blood Transfus*. 2015;13(3):484–97.
 33. Samarkanova D, Codinach M, Aran G, Guitart M, Valdivia E, Martorell LL, et al. Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts. *Blood Transfus*. 2025;23(2):147–57. <https://doi.org/10.2450/BloodTransfus.761>
 34. Khodabux CM, van Beckhoven JM, Scharenberg JG, El Barjaji F, Slot MC, Brand A. Processing cord blood from premature infants into autologous red-blood-cell products for transfusion. *Vox Sang*. 2011;100(4):367–73. <https://doi.org/10.1111/j.1423-0410.2010.01440.x>
 35. van Daelen JH, Bestebroer J, Korsten H, Vermeulen C, Reiss IKM, Lopriore E, et al. Development and production of allogeneic cord blood-derived red blood cell concentrates for transfusion to extremely preterm neonates, the All-Cord study. *Transfusion*. 2025. <https://doi.org/10.1111/trf.70024>. Epub ahead of print.
 36. Bilgin YM, van de Watering LM, Brand A. Clinical effects of leucoreduction of blood transfusions. *Neth J Med*. 2011;69(10):441–50.
 37. European Directorate for the Quality of Medicines & Health-Care (EDQM). Guide to the preparation, use and quality assurance of blood components. 22nd ed. Strasbourg: Council of Europe; 2025.
 38. Mazon MC. Déleucocytation et infection par le cytomégalo-virus [Leukocyte depletion and infection by cytomegalovirus]. *Transfus Clin Biol*. 2000;7(Suppl 1):31s–35s. [https://doi.org/10.1016/s1246-7820\(00\)80013-0](https://doi.org/10.1016/s1246-7820(00)80013-0)
 39. Crispin PJ, Edwards D, Beattie K, Brown K, Clarke L, King F, et al. Serological screening for cytomegalovirus in a leucodepleted blood supply: a systematic review. *Vox Sang*. 2026. <https://doi.org/10.1111/vox.70219>. Epub ahead of print.
 40. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉDSL, Bhatia J, et al. Innate immunity of neonates and infants. *Front Immunol*. 2018;9:1759. <https://doi.org/10.3389/fimmu.2018.01759>
 41. Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? *Transfus Apher Sci*. 2022;61(2):103402. <https://doi.org/10.1016/j.transci.2022.103402>
 42. Parkman R, Mosier D, Umansky I, Cochran W, Carpenter CB, Rosen FS. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. *N Engl J Med*. 1974;290(7):359–63. <https://doi.org/10.1056/NEJM197402142900703>
 43. Elliot J, Narayan S, Poles D, Tuckley V, Bolton-Maggs PHB. Missed irradiation of cellular blood components for vulnerable patients: insights from 10 years of SHOT data. *Transfusion*. 2021;61(2):385–92. <https://doi.org/10.1111/trf.16189>
 44. Foukaneli T, Kerr P, Bolton-Maggs PHB, Cardigan R, Coles A, Gennery A, et al. Guidelines on the use of irradiated blood components. *Br J Haematol*. 2020;191(5):704–24. <https://doi.org/10.1111/bjh.17015>
 45. Qadri SM, Chen D, Schubert P, Devine DV, Sheffield WP. Early γ -irradiation and subsequent storage of red cells in SAG-M additive solution potentiate energy imbalance, microvesiculation and susceptibility to stress-induced apoptotic cell death. *Vox Sang*. 2017;112(5):480–3. <https://doi.org/10.1111/vox.12518>
 46. Saito-Benz M, Bennington K, Gray CL, Murphy WG, Flanagan P, Steiner F, et al. Effects of freshly irradiated vs irradiated and stored red blood cell transfusion on cerebral oxygenation in preterm infants: a randomized clinical trial. *JAMA Pediatr*. 2022;176(5):e220152. <https://doi.org/10.1001/jamapediatrics.2022.0152>

47. European Parliament and Council of the European Union. Regulation (EU) 2024/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC (Text with EEA relevance). Eur Union 2024; L 17.07.2024: 1-80 [cited 2026 Mar 7]. Available from: <https://eur-lex.europa.eu/eli/reg/2024/1938/oj/eng>
48. Euro GTP II. [Cited 2026 Mar 5]. Available from: <https://tool.goodtissuepractices.site/indexB.html>

How to cite this article: Pellegrino C, Papacci P, Dani C, Cresi F, Remaschi G, Ansaldi G, et al. Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial. *Transfusion*. 2026. <https://doi.org/10.1111/trf.70241>